|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
DE60113161T2
(de)
*
|
2000-08-04 |
2006-06-14 |
Warner Lambert Co |
Verfahren zur herstellung von 2-(4-pyridyl)amino-6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on-derivaten
|
|
JP2004505974A
(ja)
*
|
2000-08-04 |
2004-02-26 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
|
|
DE60206363T2
(de)
*
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
AU2002233706C1
(en)
*
|
2001-02-26 |
2005-12-22 |
Tanabe Seiyaku Co., Ltd. |
Pyridopyrimidine or naphthyridine derivative
|
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
|
PL220952B1
(pl)
|
2002-01-22 |
2016-01-29 |
Warner Lambert Co |
2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
|
|
MXPA05001332A
(es)
|
2002-08-06 |
2005-04-28 |
Hoffmann La Roche |
6-alcoxi-pirido-pirimidinas como inhibidores de cinasa del map p-38.
|
|
US7112676B2
(en)
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
|
BRPI0409366A
(pt)
|
2003-04-10 |
2006-04-25 |
Hoffmann La Roche |
compostos de pirimido
|
|
NZ544609A
(en)
|
2003-07-11 |
2008-07-31 |
Warner Lambert Co |
Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
|
|
BRPI0412259B1
(pt)
|
2003-07-22 |
2019-08-20 |
Astex Therapeutics Limited |
Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
|
|
EP1651605B1
(en)
|
2003-07-29 |
2012-05-02 |
Xenon Pharmaceuticals Inc. |
Pyridyl derivatives and their use as therapeutic agents
|
|
PL1685131T3
(pl)
*
|
2003-11-13 |
2007-08-31 |
Hoffmann La Roche |
Hydroksyalkilo-podstawione pirydo-7-pirymidyn-7-ony
|
|
EP1699477A2
(en)
*
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
US7968557B2
(en)
*
|
2004-02-14 |
2011-06-28 |
Novartis Ag |
Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
|
|
BRPI0507852A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Warner Lambert Co |
2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
|
|
EP1740184A1
(en)
*
|
2004-03-30 |
2007-01-10 |
Pfizer Products Incorporated |
Combinations of signal transduction inhibitors
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
PL2298768T3
(pl)
*
|
2004-06-11 |
2013-03-29 |
Japan Tobacco Inc |
Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
|
|
EP1811991B1
(en)
|
2004-11-10 |
2018-11-07 |
Genzyme Corporation |
Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
|
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
AU2006207325B2
(en)
*
|
2005-01-21 |
2012-08-16 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
WO2006077424A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
BRPI0606319A2
(pt)
*
|
2005-01-21 |
2009-06-16 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
|
US8680092B2
(en)
|
2005-02-25 |
2014-03-25 |
Ono Pharmaceutical Co., Ltd. |
Nitrogenous heterocyclic compound and medicinal use thereof
|
|
PE20100737A1
(es)
*
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
UY29439A1
(es)
*
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
DK1879573T3
(da)
|
2005-05-10 |
2013-02-25 |
Incyte Corp |
Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
|
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
|
EP1931667A1
(en)
*
|
2005-09-28 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
HRP20130902T1
(hr)
*
|
2005-10-07 |
2013-11-08 |
Exelixis Inc. |
PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
|
|
JP5480503B2
(ja)
*
|
2005-10-07 |
2014-04-23 |
エクセリクシス， インク． |
ＰＩ３Ｋαのピリドピリミジノン型阻害剤
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
SI2032134T1
(sl)
|
2006-05-09 |
2015-10-30 |
Genzyme Corporation |
Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
|
|
AU2007297286A1
(en)
*
|
2006-09-08 |
2008-03-20 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
|
DK2074122T5
(da)
|
2006-09-15 |
2014-03-17 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
BRPI0715566A2
(pt)
*
|
2006-10-16 |
2013-07-02 |
Gpc Biotech Inc |
composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
|
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
EP2094698A1
(en)
*
|
2006-11-09 |
2009-09-02 |
F. Hoffmann-Roche AG |
Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
US8912177B2
(en)
|
2007-10-05 |
2014-12-16 |
Genzyme Corporation |
Method of treating polycystic kidney diseases with ceramide derivatives
|
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
EP2278973B1
(en)
|
2008-04-07 |
2011-11-02 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
EP2824100B1
(en)
|
2008-07-08 |
2018-02-21 |
Incyte Holdings Corporation |
1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
WO2010014554A1
(en)
|
2008-07-28 |
2010-02-04 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
|
NZ591176A
(en)
*
|
2008-08-22 |
2012-11-30 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
|
US20110224227A1
(en)
*
|
2008-10-01 |
2011-09-15 |
Sharpless Norman E |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
|
EP2341906A4
(en)
|
2008-10-01 |
2012-06-13 |
Univ North Carolina |
HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER
|
|
RU2578947C2
(ru)
*
|
2008-10-03 |
2016-03-27 |
Джензайм Корпорейшн |
Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
|
|
JO2885B1
(en)
*
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
US9447089B2
(en)
|
2009-04-03 |
2016-09-20 |
Plexxikon Inc. |
Compositions and uses thereof
|
|
EP2429566B1
(en)
|
2009-05-13 |
2016-01-06 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011025006A1
(ja)
*
|
2009-08-31 |
2011-03-03 |
日本ケミファ株式会社 |
Ｇｐｒ１１９作動薬
|
|
CN102648200A
(zh)
*
|
2009-10-09 |
2012-08-22 |
亚弗克希斯公司 |
用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
|
|
PH12012500900A1
(en)
|
2009-11-06 |
2012-11-12 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2011075616A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
ES2689177T3
(es)
*
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
|
EP2580217A4
(en)
*
|
2010-06-10 |
2014-06-18 |
Afraxis Holdings Inc |
6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
ES2685171T3
(es)
|
2010-06-14 |
2018-10-05 |
The Scripps Research Institute |
Reprogramación de células a un nuevo destino
|
|
CN103200822B
(zh)
|
2010-08-05 |
2014-12-24 |
天普大学-联邦高等教育体系 |
2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
EP2632467B1
(en)
|
2010-10-25 |
2016-06-22 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
EP2640394A4
(en)
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
|
WO2012129344A1
(en)
*
|
2011-03-23 |
2012-09-27 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
JP2014522396A
(ja)
|
2011-05-27 |
2014-09-04 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
置換２−ベンジリデン−２Ｈ−ベンゾ［ｂ］［１，４］チアジン−３（４Ｈ）−オン、その誘導体及びその治療上の使用
|
|
SG11201405007QA
(en)
*
|
2012-03-14 |
2014-10-30 |
Lupin Ltd |
Heterocyclyl compounds
|
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
EP2861595B9
(en)
|
2012-06-13 |
2017-06-21 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
HUE055502T2
(hu)
|
2012-07-11 |
2021-11-29 |
Blueprint Medicines Corp |
Fibroblaszt növekedési faktor receptor gátlók
|
|
HK1213044A1
(zh)
|
2012-08-03 |
2016-06-24 |
Foundation Medicine, Inc. |
人乳头瘤病毒作为肿瘤预後的预测因子
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014028756A1
(en)
|
2012-08-17 |
2014-02-20 |
Concert Pharmaceuticals, Inc. |
Deuterated baricitinib
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
PT2958916T
(pt)
|
2013-02-21 |
2018-11-21 |
Pfizer |
Formas sólidas de um inibidor de cdk4/6 seletivo
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
HRP20192168T1
(hr)
|
2013-03-15 |
2020-02-21 |
G1 Therapeutics, Inc. |
Privremena zaštita normalnih stanica tijekom kemoterapije
|
|
CA2904054A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Concert Pharmaceuticals, Inc. |
Deuterated palbociclib
|
|
TWI715901B
(zh)
|
2013-04-19 |
2021-01-11 |
美商英塞特控股公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
CN104470921B
(zh)
*
|
2013-05-17 |
2017-05-03 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
BR112016008849B8
(pt)
|
2013-10-25 |
2022-09-06 |
Blueprint Medicines Corp |
Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
|
|
ES3033810T3
(en)
*
|
2013-12-20 |
2025-08-08 |
Biomed Valley Discoveries Inc |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
RU2670762C2
(ru)
|
2013-12-31 |
2018-10-25 |
Хуаньчжу Фарма Ко., Лтд. |
Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
WO2015161288A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
|
|
ES2873959T3
(es)
|
2014-05-28 |
2021-11-04 |
Piramal Entpr Ltd |
Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
|
|
CA2954298A1
(en)
|
2014-07-24 |
2016-01-28 |
Beta Pharma, Inc. |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
|
WO2016015597A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
|
US20170217962A1
(en)
*
|
2014-07-31 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
TW201618773A
(zh)
*
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
|
|
US20170240543A1
(en)
*
|
2014-08-14 |
2017-08-24 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
HUE061672T2
(hu)
|
2014-11-12 |
2023-08-28 |
Seagen Inc |
Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
|
|
CN104496983B
(zh)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
|
CN104447743B
(zh)
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
EP3251672B1
(en)
|
2014-12-31 |
2023-02-01 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor
|
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Ｃｄｋ類小分子抑制劑的化合物及其用途
|
|
MX388991B
(es)
|
2015-02-20 |
2025-03-20 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr)
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
WO2016169422A1
(zh)
*
|
2015-04-22 |
2016-10-27 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
CA2987019C
(en)
*
|
2015-05-29 |
2023-09-26 |
Teijin Pharma Limited |
Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
|
MX376083B
(es)
|
2015-06-04 |
2025-03-07 |
Pfizer |
Formas de dosificacion solidas de palbociclib.
|
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
EP3543235A1
(en)
|
2015-08-05 |
2019-09-25 |
ratiopharm GmbH |
Crystalline form and acetic acid adduct of palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
CN106632311B
(zh)
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
|
WO2017101763A1
(en)
|
2015-12-13 |
2017-06-22 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
|
JP6663021B2
(ja)
*
|
2015-12-31 |
2020-03-11 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
|
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
|
JP6921115B2
(ja)
*
|
2016-04-22 |
2021-08-18 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法
|
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
MX2019000200A
(es)
|
2016-07-01 |
2019-09-26 |
G1 Therapeutics Inc |
Agentes antiproliferativos basados en pirimidina.
|
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
|
WO2018009735A1
(en)
|
2016-07-07 |
2018-01-11 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
|
CU24522B1
(es)
*
|
2016-08-15 |
2021-06-08 |
Pfizer |
PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
|
|
KR102466192B1
(ko)
|
2016-08-23 |
2022-11-14 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
간세포성 암종의 치료를 위한 조합 요법
|
|
CN110022900A
(zh)
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
ES2934846T3
(es)
|
2016-10-20 |
2023-02-27 |
Pfizer |
Inhibidores de CDK para tratamiento de PAH
|
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
|
WO2018089518A1
(en)
|
2016-11-08 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
EP3541389A1
(en)
|
2016-11-16 |
2019-09-25 |
Pfizer Inc |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
HUE057706T2
(hu)
|
2016-11-28 |
2022-05-28 |
Teijin Pharma Ltd |
Pirido[3,4-d]pirimiden-származék vagy szolvátja kristálya
|
|
HUE053220T2
(hu)
|
2016-11-28 |
2021-06-28 |
Teijin Pharma Ltd |
((Piridin-2-il)-amino)pirido[3,4-d]pirimidin és ((piridazin-3-il)-amino)pirido[3,4-d]pirimidin származékok mint CDK4/6 inhibitorok pl. reumatoid artritisz, érelmeszesedés, tüdõfibrózis, agyi infartus vagy rák kezelésére
|
|
JP7044801B2
(ja)
|
2016-12-16 |
2022-03-30 |
シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド |
Ｃｄｋ４／６阻害剤
|
|
IL267795B2
(en)
|
2017-01-06 |
2023-02-01 |
G1 Therapeutics Inc |
Combination therapy for the treatment of cancer
|
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业（江苏）有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
|
US10729692B2
(en)
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
|
CN110809576B
(zh)
*
|
2017-03-03 |
2022-08-30 |
奥克兰联合服务有限公司 |
Fgfr激酶抑制剂和药物用途
|
|
RU2764724C2
(ru)
|
2017-03-16 |
2022-01-19 |
ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. |
Комбинированная терапия для лечения рака молочной железы
|
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
SG11201911859QA
(en)
|
2017-06-16 |
2020-01-30 |
Beta Pharma Inc |
Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
|
|
IL315143A
(en)
|
2017-06-29 |
2024-10-01 |
G1 Therapeutics Inc |
Morphic forms of g1t38 and methods of manufacture thereof
|
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
|
EP3658119A1
(en)
|
2017-07-28 |
2020-06-03 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
|
CN111433375B
(zh)
|
2017-08-31 |
2024-07-30 |
诺华股份有限公司 |
选择针对癌症患者的治疗的方法
|
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
US11667651B2
(en)
|
2017-12-22 |
2023-06-06 |
Hibercell, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
|
KR20200115583A
(ko)
|
2018-01-29 |
2020-10-07 |
베타 파마, 인크. |
Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
|
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
|
CA3090493A1
(en)
|
2018-02-06 |
2019-08-15 |
The Board Of Trustees Of The University Of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
|
US20200405809A1
(en)
|
2018-02-27 |
2020-12-31 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
|
|
BR112020017421A2
(pt)
|
2018-02-27 |
2020-12-22 |
Incyte Corporation |
Imidazopirimidinas e triazolopirimidinas como inibidores de a2a/a2b
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
EP3788047B1
(en)
|
2018-05-04 |
2024-09-04 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
AU2019269159A1
(en)
|
2018-05-14 |
2020-11-19 |
Pfizer Inc. |
Oral solution formulation
|
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
|
WO2019224194A1
(en)
|
2018-05-24 |
2019-11-28 |
Synthon B.V. |
A process for making palbociclib
|
|
IL300821B2
(en)
|
2018-07-05 |
2025-05-01 |
Incyte Holdings Corp |
Fused pyrazine derivatives as A2A/A2B inhibitors
|
|
WO2020023297A1
(en)
|
2018-07-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating cancer with pi3k inhibitor, gdc-0077
|
|
SG11202101807SA
(en)
|
2018-08-24 |
2021-03-30 |
G1 Therapeutics Inc |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
WO2020076432A1
(en)
|
2018-10-08 |
2020-04-16 |
Genentech, Inc. |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
TW202035406A
(zh)
*
|
2018-12-07 |
2020-10-01 |
大陸商杭州英創醫藥科技有限公司 |
作為cdk-hdac雙通路抑制劑的雜環化合物
|
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
|
EP3902805A4
(en)
|
2018-12-28 |
2023-03-01 |
SPV Therapeutics Inc. |
CYCLINE-DEPENDENT KINASE INHIBITORS
|
|
US20230048132A1
(en)
*
|
2018-12-28 |
2023-02-16 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
TW202045181A
(zh)
*
|
2019-02-15 |
2020-12-16 |
美商英塞特公司 |
細胞週期蛋白依賴性激酶2生物標記物及其用途
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
WO2020253808A1
(zh)
*
|
2019-06-20 |
2020-12-24 |
江苏恒瑞医药股份有限公司 |
一种药物组合物以及其制备方法
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
MX2022000279A
(es)
|
2019-07-07 |
2022-02-03 |
Olema Pharmaceuticals Inc |
Regimenes de antagonistas del receptor de estrogeno.
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US20210030869A1
(en)
|
2019-08-01 |
2021-02-04 |
Incyte Corporation |
Dosing regimen for an ido inhibitor
|
|
KR20220064369A
(ko)
|
2019-08-14 |
2022-05-18 |
인사이트 코포레이션 |
Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN119930610A
(zh)
|
2019-10-11 |
2025-05-06 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
|
CN114901659A
(zh)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
作为jak抑制剂的稠合嘧啶吡啶酮化合物
|
|
WO2021113219A1
(en)
|
2019-12-03 |
2021-06-10 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
US11897891B2
(en)
|
2019-12-04 |
2024-02-13 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CR20220285A
(es)
|
2019-12-04 |
2022-10-27 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
|
MX2022007488A
(es)
|
2019-12-16 |
2022-08-02 |
Lunella Biotech Inc |
Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
|
|
BR112022011758A2
(pt)
|
2019-12-16 |
2022-08-30 |
Lunella Biotech Inc |
Terapêutica de câncer inibidor de cdk4/6 seletivo
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021176349A1
(en)
|
2020-03-05 |
2021-09-10 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
JP7549032B2
(ja)
*
|
2020-03-13 |
2024-09-10 |
プロセネスター エルエルシー |
ＣＤＫ阻害剤としてのピリド［２，３－ｄ］ピリミジン－７（８Ｈ）－オン
|
|
CN114245753A
(zh)
*
|
2020-03-27 |
2022-03-25 |
江苏康宁杰瑞生物制药有限公司 |
用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
|
|
US20210355121A1
(en)
|
2020-04-16 |
2021-11-18 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
EP4153597B1
(en)
|
2020-05-19 |
2025-09-10 |
Pharmacosmos Holding A/S |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
|
IL299871A
(en)
|
2020-07-15 |
2023-03-01 |
Pfizer |
Kat6 inhibitor methods and combinations for cancer treatment
|
|
EP4181919A1
(en)
|
2020-07-20 |
2023-05-24 |
Pfizer Inc. |
Combination therapy
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US20240287065A1
(en)
*
|
2021-06-09 |
2024-08-29 |
Tyk Medicines (Zhengzhou) , Inc. |
Compound as cdk kinase inhibitor and use thereof
|
|
JP2024522188A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
TW202313611A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
KR20240032915A
(ko)
|
2021-07-07 |
2024-03-12 |
인사이트 코포레이션 |
Kras의 저해제로서의 삼환식 화합물
|
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
|
US12350276B2
(en)
|
2021-07-26 |
2025-07-08 |
Celcuity Inc. |
Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
|
CN118119393A
(zh)
*
|
2021-09-14 |
2024-05-31 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
US12030884B2
(en)
|
2021-10-01 |
2024-07-09 |
Incyte Corporation |
Pyrazoloquinoline KRAS inhibitors
|
|
CR20240197A
(es)
|
2021-10-14 |
2024-08-07 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
AU2022389961A1
(en)
|
2021-11-22 |
2024-06-06 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3240454A1
(en)
|
2021-12-10 |
2023-06-15 |
Lacey Morgan LITCHFIELD |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
|
|
US20250049802A1
(en)
|
2021-12-14 |
2025-02-13 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
US20230192722A1
(en)
|
2021-12-22 |
2023-06-22 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
CR20240408A
(es)
|
2022-03-07 |
2024-11-22 |
Incyte Corp |
Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
|
|
HU231594B1
(hu)
*
|
2022-05-10 |
2025-03-28 |
Egis Gyógyszergyár Zrt. |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
|
AR129675A1
(es)
|
2022-06-22 |
2024-09-18 |
Incyte Corp |
Inhibidores de cdk12 de aminas biciclicas
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
|
WO2024023703A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
|
KR20250076543A
(ko)
|
2022-08-31 |
2025-05-29 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제의 투여량 요법
|
|
CN120456897A
(zh)
|
2022-11-02 |
2025-08-08 |
佩特拉制药公司 |
用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
|
|
EP4615431A1
(en)
|
2022-11-11 |
2025-09-17 |
Astrazeneca AB |
Combination therapies for the treatment of cancer
|
|
TW202440571A
(zh)
*
|
2022-12-16 |
2024-10-16 |
大陸商上海岸闊醫藥科技有限公司 |
化合物及其用途
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
|
WO2024220532A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
TW202446371A
(zh)
|
2023-04-18 |
2024-12-01 |
美商英塞特公司 |
２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
|
|
WO2024231275A1
(en)
|
2023-05-05 |
2024-11-14 |
Astrazeneca Ab |
Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
US20250177414A1
(en)
|
2023-12-04 |
2025-06-05 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|